We live in an era where it's possible to diagnose a disease long before the symptoms begin to appear, and Dx companies are at the forefront of this frontier. While the potential is great, some might wonder what profit there is in the field right now. Well, here's a list that may help clarify that.
Below is a list of 10 CEOs of publicly traded companies focused on diagnostics, as opposed to drug discovery or tools/tech, as ranked by their total 2012 compensation as disclosed in proxy reports (Form DEF 14As filed by U.S.-based companies), Form 20-Fs (filed by overseas-based companies), and S-1 registration statements (filed by newly public companies).
Each listing includes the names, titles, and companies of each listed CEO; their compensation for 2012 and 2011, recorded as calendar years unless noted otherwise; the percentage change between 2011–2012 compensation; and footnotes that explain wide discrepancies in compensation or other information.
A few observations from the results: Diagnostics CEOs generally don’t get paid as much as their drug discovery and tools/tech counterparts, more than likely because the companies are younger than legacy pharmas, biotech giants, and tools/tech developers. None of the diagnostics CEOs were paid above $6 million, compared to seven tools/tech CEOs, not to mention the eight-figure compensation packages routine for biopharma leaders. However, the top 10 were all compensated above $1 million, followed by another handful of diagnostics CEOs not appearing on this list, who were paid in the high six figures—and who are likely to reach the million-dollar level as their companies continue to grow. Two women appear among the top 10 compensated diagnostics CEOs, compared to zero in the biopharma and tools/tech lists.